AR125315A1 - Polipéptido combinado artificial de muerte celular/sistema reportero para célula receptora de antígeno quimérico y sus usos - Google Patents

Polipéptido combinado artificial de muerte celular/sistema reportero para célula receptora de antígeno quimérico y sus usos

Info

Publication number
AR125315A1
AR125315A1 ARP220100881A ARP220100881A AR125315A1 AR 125315 A1 AR125315 A1 AR 125315A1 AR P220100881 A ARP220100881 A AR P220100881A AR P220100881 A ARP220100881 A AR P220100881A AR 125315 A1 AR125315 A1 AR 125315A1
Authority
AR
Argentina
Prior art keywords
cell
polypeptide
cell death
artificial
reporter system
Prior art date
Application number
ARP220100881A
Other languages
English (en)
Inventor
Michael Francis Naso
Luis Borges
Budda Gurung
Original Assignee
Century Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Century Therapeutics Inc filed Critical Century Therapeutics Inc
Publication of AR125315A1 publication Critical patent/AR125315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/035—Herpes simplex virus I or II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70592—CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un polipéptido combinado artificial de muerte celular / sistema reportero que contiene una timidina quinasa del virus del herpes simple (HSV-tk) fusionada con un polipéptido de antígeno de membrana específico de próstata (PSMA) mediante un enlace. También se describen polinucleótidos que codifican el polipéptido artificial de muerte celular, células que expresan el polipéptido artificial de muerte celular y métodos relacionados. Reivindicación 1: Un polinucleótido que codifica un polipéptido combinado artificial de muerte celular / sistema reportero que comprende un dominio intracelular que tiene una timidina quinasa del virus del herpes simple (HSV-tk) y un enlace, una región transmembrana, y un dominio extracelular que comprende un dominio extracelular de antígeno de membrana específico de próstata (PSMA) o un fragmento de este. Reivindicación 11: Un polinucleótido que codifica un polipéptido CD24 combinado artificial de muerte celular / sistema reportero que comprende un cúmulo de diferenciación 24 (CD24) fusionado con un dominio extracelular de antígeno de membrana específico de próstata (PSMA) o un fragmento de este mediante un enlace peptídico. Reivindicación 19: Un polinucleótido que codifica un polipéptido combinado CD52 artificial de muerte celular / sistema reportero que comprende un cúmulo de diferenciación 52 (CD52) fusionado con una timidina quinasa del virus del herpes simple (HSV-tk) o un fragmento de esta mediante un enlace peptídico. Reivindicación 29: Una célula, tal como una célula inmunitaria, una célula madre pluripotente inducida (iPSC) o una célula derivada de esta que comprende el polinucleótido de acuerdo con cualquiera de las reivindicaciones 1 - 26 o el vector de la reivindicación 28, donde el polipéptido PSMA se expresa extracelularmente y la HSV-tk se expresa intracelularmente Reivindicación 31: Un método para eliminar la célula de acuerdo con la reivindicación 29 o 30, que comprende poner en contacto la célula con el único o los varios agentes que se unen al polipéptido artificial de muerte celular para así inducir la muerte de la célula. Reivindicación 34: Un método para producir una célula que expresa el polipéptido combinado artificial de muerte celular / sistema reportero, que comprende introducir el polinucleótido de acuerdo con cualquiera de las reivindicaciones 1 - 26 o el vector de la reivindicación 28 en una célula para así producir la célula que expresa el polipéptido combinado artificial de muerte celular / sistema reportero.
ARP220100881A 2021-04-07 2022-04-07 Polipéptido combinado artificial de muerte celular/sistema reportero para célula receptora de antígeno quimérico y sus usos AR125315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163171652P 2021-04-07 2021-04-07

Publications (1)

Publication Number Publication Date
AR125315A1 true AR125315A1 (es) 2023-07-05

Family

ID=81579718

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100881A AR125315A1 (es) 2021-04-07 2022-04-07 Polipéptido combinado artificial de muerte celular/sistema reportero para célula receptora de antígeno quimérico y sus usos

Country Status (9)

Country Link
US (1) US20220332782A1 (es)
EP (1) EP4319799A1 (es)
JP (1) JP2024513454A (es)
CN (1) CN117479952A (es)
AR (1) AR125315A1 (es)
AU (1) AU2022253223A1 (es)
CA (1) CA3214661A1 (es)
TW (1) TW202304962A (es)
WO (1) WO2022216524A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2024103017A2 (en) 2022-11-10 2024-05-16 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8846395B2 (en) 2005-06-01 2014-09-30 Wisconsin Alumni Research Foundation Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors
KR100902340B1 (ko) 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
EP3447128A1 (en) 2008-06-04 2019-02-27 FUJIFILM Cellular Dynamics, Inc. Methods for the production of ips cells using non-viral approach
EP2336303B1 (en) 2008-09-08 2015-07-15 Riken NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM
CA2753679C (en) 2009-02-27 2021-03-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
HRP20221195T1 (hr) 2009-03-19 2022-12-09 The Johns Hopkins University Spojevi koji ciljaju psma i njihova uporaba
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
CA2806858C (en) 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
CA2826386C (en) 2011-02-08 2020-04-28 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
US11124845B2 (en) 2014-03-18 2021-09-21 The Johns Hopkins University PSMA-based molecular-genetic reporter system
AU2015290554A1 (en) 2014-07-18 2017-03-09 Kyoto University Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells
EP3365433A1 (en) 2015-10-20 2018-08-29 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
JP6948072B2 (ja) 2016-04-15 2021-10-13 国立大学法人京都大学 Ｃｄ８陽性ｔ細胞を誘導する方法
US20220025001A1 (en) * 2016-04-28 2022-01-27 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
KR20230167769A (ko) 2016-08-26 2023-12-11 베이롤 칼리지 오브 메드신 세포 치료요법을 위한 항상성 활성 사이토킨 수용체
JP7215994B2 (ja) 2016-09-06 2023-01-31 ザ チルドレンズ メディカル センター コーポレーション 人工多能性幹細胞由来の免疫細胞
CA3056261A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
WO2019060695A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. CHIMERIC POLYPEPTIDES AND USES THEREOF
JP2021514185A (ja) 2018-02-14 2021-06-10 サニーブルック リサーチ インスティチュート Ｔ細胞系列の細胞を発生させるための方法
US20210107993A1 (en) * 2018-03-07 2021-04-15 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use

Also Published As

Publication number Publication date
CA3214661A1 (en) 2022-10-13
EP4319799A1 (en) 2024-02-14
JP2024513454A (ja) 2024-03-25
WO2022216524A1 (en) 2022-10-13
AU2022253223A9 (en) 2024-02-22
CN117479952A (zh) 2024-01-30
AU2022253223A1 (en) 2023-09-28
TW202304962A (zh) 2023-02-01
US20220332782A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
AR125315A1 (es) Polipéptido combinado artificial de muerte celular/sistema reportero para célula receptora de antígeno quimérico y sus usos
CL2021001986A1 (es) Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1).
AR109451A1 (es) Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión
MX2017007634A (es) Métodos para producir polipéptidos modificados por ctp de acción prolongada.
HRP20210076T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma
BR112018012826A2 (pt) método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
PE20211660A1 (es) Neoantigenos prostaticos y sus usos
AR020331A1 (es) Construccion, y metodo para producir una proteina en una celula de planta
PH12017502080A1 (en) Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
CL2023001434A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
MX2022000367A (es) Heterodimeros, metodos y uso de los mismos.
UY37644A (es) Polipéptidos quiméricos y métodos para alterar su localización en la membrana
Avinoam et al. Eukaryotic cell–cell fusion families
AR096314A1 (es) Métodos para la producción y/o purificación de hormonas
Rouaud et al. R40. 76 binds to the α domain of ZO-1: Role of ZO-1 (α+) in epithelial differentiation and mechano-sensing
CO2023012586A2 (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
BRPI0514869A (pt) gene responsivo a sal para geração de plantas transgênicas resistentes a sal
CO2022017056A2 (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
BR112023011689A2 (pt) Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero
AR076948A1 (es) Anticuerpos contra ccn1 (proteina rica en cisteina 61-cyr-61) humano y usos de los mismos
KR102121817B1 (ko) Crispr 편집 기술을 이용한 재조합 항원을 발현시키는 벡터 및 이를 동시에 다중 삽입시키는 방법
Yao STRUCTURE AND FUNCTION OF A NEWLY DISCOVERED NON-CATALYTIC PI3K ENDOCYTIC BEHAVIOR
AR122163A1 (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
AR126157A1 (es) Receptores que proporcionan coestimulación dirigida para terapia celular adoptiva

Legal Events

Date Code Title Description
FB Suspension of granting procedure